Vital Signs - Benchtop Automation: Accelerating Bench to Bedside

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on April 25, 2011, provides analyts's summary of the American Association of Cancer Research (AACR) annual meeting.

Additionally, a company spotlight is provided for QuantaLife, a venture-backed startup company based in Pleasanton, Calif., developing third-generation of Polymerase Chain Reaction (PCR) technology that provides an absolute quantification measurement of target molecules in nanoliter droplet form. Reimbursement and regulatory news from the FDA is also provided for week of April 4, 2011.

Table of Contents

Vital Signs - Benchtop Automation: Accelerating Bench to BedsideVital Signs: 25 Apr 2011This week's issue




Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.